Experts have some thoughts
Furthermore, the demonstration of cardiovascular benefits across a broad range of adiposity levels, coupled with independence from weight loss magnitude, suggests that semaglutide and perhaps other GLP-1 receptor agonists should be reconceptualized as cardiovascular disease-modifying agents rather than solely medications for glycemic control or weight loss
Statements Author contributions ZT: Writing original draft
This article explores the safety profile of glutathione, how it interacts with liver function, and why the way you take it matters more than the dose itself
5A) revealed that single biomarkers (e.g., serum CRP and triglycerides) have limited discriminative power, whereas integrated domainsphospholipid remodeling, lipotoxicity, and mitochondrial dysfunctiontogether with antioxidant status, acute phase response, and reduced ApoA1are the principal contributors